Etiology, Pathophysiology, and Treatment of Atrial Fibrillation Part 1

被引:18
|
作者
Arortow, Wilbert S. [1 ]
机构
[1] New York Med Coll, Westchester Med Ctr, Div Cardiol, Dept Med, Valhalla, NY 10595 USA
关键词
atrial fibrillation; beta blockers; stroke; cardiovascular disease; cardioversion; digoxin; calcium channel blockers; radiofrequency catheter ablation; pacemakers; antiarrhythmic drugs;
D O I
10.1097/CRD.0b013e31816de1e3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, verapamil, or diltiazem may be given to immediately slow a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nonpharmacologic therapies should be used in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. This is part 1 of a 2-part review of the etiology, pathophysiology, and treatment of atrial fibrillation. The second part will be published in the subsequent issue of Cardiology in Review.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
  • [41] Atrial Fibrillation Epidemiology, Pathophysiology, and Clinical Outcomes
    Staerk, Laila
    Sherer, Jason A.
    Ko, Darae
    Benjamin, Emelia J.
    Helm, Robert H.
    CIRCULATION RESEARCH, 2017, 120 (09) : 1501 - 1517
  • [42] Atrial fibrillation: pathophysiology, genetic and epigenetic mechanisms
    Vinciguerra, Manlio
    Dobrev, Dobromir
    Nattel, Stanley
    LANCET REGIONAL HEALTH-EUROPE, 2024, 37
  • [43] Roles of Major Chemokines in the Pathophysiology of Atrial Fibrillation
    Rafaqat, Saira
    Bibi, Fozia
    Murad, Muhammad Aqib
    Khurshid, Huma
    Sheerin, Amna
    CARDIOVASCULAR INNOVATIONS AND APPLICATIONS, 2024, 9 (01)
  • [44] Canine atrial fibrillation: Pathophysiology, epidemiology and classification
    Pedro, Brigite
    Fontes-Sousa, Ana Patricia
    Gelzer, Anna R.
    VETERINARY JOURNAL, 2020, 265
  • [45] Pathophysiology, molecular mechanisms, and genetics of atrial fibrillation
    Han, Pan
    Zhao, Xinxin
    Li, Xuexun
    Geng, Jing
    Ni, Shouxiang
    Li, Qiao
    HUMAN CELL, 2024, 38 (01)
  • [46] Calcium in the Pathophysiology of Atrial Fibrillation and Heart Failure
    Denham, Nathan C.
    Pearman, Charles M.
    Caldwell, Jessica L.
    Madders, George W. P.
    Eisner, David A.
    Trafford, Andrew W.
    Dibb, Katharine M.
    FRONTIERS IN PHYSIOLOGY, 2018, 9
  • [47] Pathophysiology of atrial fibrillation and chronic kidney disease
    Ding, Wern Yew
    Gupta, Dhiraj
    Wong, Christopher F.
    Lip, Gregory Y. H.
    CARDIOVASCULAR RESEARCH, 2021, 117 (04) : 1046 - 1059
  • [48] Recent advances in the molecular pathophysiology of atrial fibrillation
    Wakili, Reza
    Voigt, Niels
    Kaeaeb, Stefan
    Dobrev, Dobromir
    Nattell, Stanley
    JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (08): : 2955 - 2968
  • [49] Role of neural modulation in the pathophysiology of atrial fibrillation
    Male, Shailesh
    Scherlag, Benjamin J.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2014, 139 : 512 - 522
  • [50] Pathophysiology of atrial fibrillation: Focal patterns of activation
    de Groot, Natasja M. S.
    Allessie, Maurits A.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2019, 42 (10): : 1312 - 1319